A prime test for the laboratory diagnosis of myasthenia gravis (MG).
Detection of “subclinical MG” in D-penicillamine recipients, in patients with thymoma without clinical evidence of MG, and in patients with graft-versus-host disease.
Distinguish acquired disease (90% positive) from congenital disease (negative).
Monitoring of disease progression in MG or response to immunotherapy.
A complement to the P/Q type calcium channel binding antibody test as a diagnostic aid for Lambert-Eaton myasthenic syndrome (LES) or primary lung carcinoma.